Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. We show 27 historical shares outstanding datapoints in our CRNX shares outstanding history coverage, used to compute CRNX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CRNX market cap history over the course of time is important for investors
interested in comparing CRNX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CRNX versus a peer is one thing; comparing
CRNX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CRNX can fluctuate over the course of history.
With this page we aim to empower investors researching CRNX by allowing them to research the CRNX market cap history. |
Free CRNX Email Alerts:
Video: The Importance of Market Cap
